pharmaceutical investing Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs
Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Element79 Gold Engages Rangefront Mining Services to Prepare NI 43-101 Technical Report on Gold Mountain Project; Site Visit Completed
Forte Minerals Engages Strategic Advisors, Expands Capital Markets Team, and Launches AI-Powered Investor Tool
